Form 4: Tharimmune Director Kelly Anderson Acquires Options in Latest SEC Filing

Director Kelly Anderson receives options to purchase 2,353 shares of Tharimmune common stock, according to a recent SEC Form 4 filing.

Summary

• On August 9, 2024, Kelly Anderson, a director of Tharimmune, Inc. (THAR), was granted options to purchase 2,353 shares of the company's common stock.
• The options have an exercise price of $2.925.
• These options were granted under the company's 2023 Omnibus Equity Incentive Plan.
• The options vest in 12 equal monthly installments, starting on the grant date.
• Following this transaction, Anderson directly owns 52,353 shares.
• The transaction was reported on August 12, 2024.

Sentiment

Score: 6

Explanation: The document is a standard SEC filing related to stock option grants, which is generally neutral. The grant itself can be seen as a positive sign of incentivizing management, but it's not a major event.

Positives

• The grant of options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages continued service and contribution to the company.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key personnel.

Comparison to Industry Standards

• Stock option grants are a common practice in the biotechnology industry to incentivize and retain key personnel.
• The vesting schedule of 12 months is fairly standard.
• Comparable companies such as Madrigal Pharmaceuticals, Viking Therapeutics, and 89bio also utilize stock options as part of their compensation packages.

Stakeholder Impact

• The option grant could potentially dilute existing shareholders if the options are exercised in the future.
• The option grant incentivizes the director, which could benefit shareholders if it leads to improved company performance.

Key Dates

Keywords

Tharimmune, Kelly Anderson, options, director, SEC Form 4, beneficial ownership, equity incentive plan, stock options, THAR